Clinical Safety

Article 1.6 of the 2026 trade pact introduces a controversial 'no-review' clause that exempts processed biotechnology products from standard Bangladeshi authority approval. This development marks a significant shift in the nation's approach to agricultural commerce, effectively placing the demands

Data derived from the Phase 3 C-POST trial provided the empirical foundation for a new dosing strategy that aims to lower the physical and emotional strain of frequent cancer treatments. This recommendation from the Committee for Medicinal Products for Human Use marks a pivotal shift in how

Magnetic resonance imaging's multiplanar capabilities allow for the identification of tubular duplications that run parallel to the segment of the fetal bowel. This sophisticated imaging modality has fundamentally shifted the diagnostic landscape for clinicians managing rare congenital anomalies

For MTX-E1, Montara Therapeutics is pairing the approved medicine everolimus with a second molecule intended to keep its activity out of peripheral tissues. The aim is to preserve the drug’s neurological benefit while reducing systemic effects that limit treatment. A successful combination could

A Software Bill of Materials acts as a critical ingredient list that allows manufacturers to identify vulnerabilities in third-party libraries before they can be exploited. This requirement has become the cornerstone of modern regulatory submissions as the medical landscape completes its radical

The reduction of intraretinal fluid in patients with Best vitelliform macular dystrophy provides an objective anatomical marker for the success of OPGx-BEST1 therapy. Modern ophthalmology is navigating a period of transformation as adeno-associated virus (AAV) gene therapies transition from